David McDermott
Chief, Division of Medical Oncology, BIDMC · Beth Israel Deaconess Medical Center
Credentials: · · ·
History
- Present
Division of Medical Oncology · Beth Israel Deaconess Medical Center
- 1995–1997
Medical Oncology
- 1992–1995
Internal Medicine
Research
Improved survival with ipilimumab in patients with metastatic melanoma
New England Journal of Medicine · 2010 · 12,191 citations
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
New England Journal of Medicine · 2012 · 10,404 citations
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2015 · 4,745 citations
133 papers
103 papers
59 papers
53 papers · 14 as a fellow
39 papers
- RM
38 papers
35 papers
30 papers
Grants
- 2003–2031
National Cancer Institute · P50
Contact PI · $32.9M · Beth Israel Deaconess Medical Center
- 2019–2028
Developing a Translation Pipeline for VHL Mutant Malignancies
National Cancer Institute · U01
Contact PI · $3.8M · Beth Israel Deaconess Medical Center
- 2021–2026
Clinical Characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma
National Cancer Institute · R01
Contact PI · $2.1M · Beth Israel Deaconess Medical Center
- 1997–2026
Dana-Farber/Harvard Cancer Center
National Cancer Institute · P30
Project lead · $529.5K · Dana-Farber Cancer Inst
Clinical trials
- 2010–2020
IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
Principal investigator · Completed
Beth Israel Deaconess Medical Center
- 2009–2015
Principal investigator · Completed · Phase 2
Beth Israel Deaconess Medical Center
- 2009–2018
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Principal investigator · Completed · Phase 2
Beth Israel Deaconess Medical Center
- 2002–2007
Principal investigator · Completed · Phase 2
Beth Israel Deaconess Medical Center